Skip to main content
Fig. 1 | Cancer Cell International

Fig. 1

From: Enhancing therapeutic efficacy in luminal androgen receptor triple-negative breast cancer: exploring chidamide and enzalutamide as a promising combination strategy

Fig. 1

Workflow of the analytical process conducted in this study. The analytical process performed in this study followed a structured framework: This study utilized multi-omics cohort from FUSCC to identify potential therapeutic targets for the LAR subtype. The efficacy of treatment strategies and potential molecular mechanisms were investigated through in vivo in vitro ex vivo drug sensitivity experiments, as well as RNA sequencing. The aim of this study was to propose potential clinical treatment strategies specifically for the LAR subtype. LAR luminal androgen receptor, IM immunomodulatory, BLIS basal-like and immune-suppressed, MES mesenchymal-like, FUSCC Fudan University Shanghai Cancer Center

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us